Results 11 to 20 of about 44,899 (264)

Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6 [PDF]

Xenobiotica, 2013
1. Metoclopramide is a widely used clinical drug in a variety of medical settings with rare acute dystonic events reported. The aim of this study was to assess a previous report of inactivation of CYP2D6 by metoclopramide, to determine the contribution of various CYPs to metoclopramide metabolism, and to identify the mono-oxygenated products of ...
Mara R, Livezey, Erran D, Briggs, Amanda K, Bolles, Leslie D, Nagy, Rina, Fujiwara, Laura Lowe, Furge   +5 more
openaire   +2 more sources

Is CYP2D6 phenotype predictable from CYP2D6 genotype? [PDF]

Microchemical Journal, 2018
Abstract Genetic polymorphism of cytochrome P450s results in clinically significant modifications in patients' drug metabolizing capacities. CYP2D6 has a crucial role in the elimination of several clinically important drugs (antiarrhythmics, beta-adrenergic blockers, psychopharmacons and analgesics); however, the prediction of the phenotypic ...
Ádám Ferenc Kiss, Katalin Tóth, Cintia Juhász, Manna Temesvári, József Paulik, Gábor Hirka, Katalin Monostory   +6 more
openaire   +2 more sources

Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan [PDF]

Clinical Pharmacology & Therapeutics, 2010
The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability.
Abduljalil, K, Frank, D, Gaedigk, A, Klaassen, T, Tomalik-Scharte, D, Jetter, A, Jaehde, U, Kirchheiner, J, Fuhr, U   +8 more
openaire   +3 more sources

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics [PDF]

, 2018
Tamoxifen reduces the rate of breast cancer recurrence by about one-half. It is converted to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6) and transported by ATP-binding cassette transporters. Genetic polymorphisms that confer reduced CYP2D6 activity or concurrent use of CYP2D6-inhibiting drugs ...
Cronin-Fenton, Deirdre P, Damkier, Per
openaire   +4 more sources

Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex Long PCR [PDF]

Clinical Chemistry, 2000
Abstract Background: Interindividual differences in CYP2D6 activity range from total absence of metabolism of certain drugs to ultrafast metabolism and can produce adverse effects or lack of therapeutic effect under standard therapy. Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity.
Hersberger, Martin, Marti-Jaun, Jacqueline, Rentsch, Katharina, Hänseler, Edgar   +3 more
openaire   +3 more sources

Pharmacogenetics of analgesic drugs [PDF]

, 2013
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R, Cregg, R, Gubbay, A, Russo, G, Sato, H   +4 more
core   +1 more source

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. [PDF]

, 2020
Determining factors that contribute to interindividual and intra-individual variability in pharmacokinetics (PKs) and drug metabolism is essential for the optimal use of drugs in humans.
Alhaja, Maher, Dorrestein, Pieter C, Jarmusch, Alan K, Knight, Rob, Liyanage, Marlon, Ma, Joseph D, Momper, Jeremiah D, Tsunoda, Shirley M, Vrbanac, Alison   +8 more
core   +1 more source

A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples

Frontiers in Pharmacology, 2023
CYP2D6 is one of the most polymorphic drug-metabolizing enzymes in the liver. While genetic CYP2D6 variants serve as clinical biomarkers to predict CYP2D6 activity, large inter-person variability in CYP2D6 expression remains unaccounted for.
Joseph M. Collins, Hannah Lester, Samia Shabnaz, Danxin Wang   +3 more
doaj   +1 more source

Towards the clinical implementation of pharmacogenetics in bipolar disorder. [PDF]

, 2014
BackgroundBipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide.
A Berghofer, A Heils, A Koski, A Serretti, A Serretti, A Serretti, A Szczepankiewicz, A Yu, AA Nierenberg, AK Malhotra, AL Zackrisson, B Alsina, B Kremeyer, C Cordon-Cardo, C Kawanishi, C O’Dushlaine, C Sears, CA Grimes, CC Zai, CE Begley, CH Chen, DA Mrazek, DE Adkins, DJ Smith, DK Hall-Flavin, DK Hall-Flavin, DL Braff, E Lessard, E Schaeffeler, EB Binder, EB Brown, EG Jonsson, EJ Peters, EK Green, EM Penas-Lledo, EM Penas-Lledo, EN Smith, ER Mardis, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, F Asztely, F Benedetti, F Czerwensky, F Holsboer, F Mamdani, FJ Gonzalez, FJ McMahon, FM Daray, FP Bymaster, FP Guengerich, FR Sallee, G Shaltiel, G Turecki, GE Simon, GENDEP Investigators, MARS Investigators, STAR*D Investigators, GR Lewin, GS Malhi, GS Sachs, H Pei, HA Garriock, HK Kroemer, I Johansson, IC Gray, J Brockmoller, J de Leon, J de Leon, J de Leon, J de Leon, J Kirchheiner, J Kirchheiner, J Thome, J Winner, JA Engelman, JA Johnson, JA Lieberman, JC Ballenger, JC Chambers, JC Stingl, JE Kootstra-Ros, JE Sarginson, JK Rybakowski, JK Rybakowski, JM Beaulieu, John R Kelsoe, JP Zhang, JP Zhang, JR Kelsoe, JS Leeder, JT Groves, K Herrlin, K Hodgson, K Yoshii, KG Mountjoy, KL Kopnisky, KR Crews, KW Lobello, L Bertilsson, L Michelon, L Tondo, LA Smith, LN Yatham, LV Kessing, M Adli, M Dmitrzak-Weglarz, M Gex-Fabry, M Ingelman-Sundberg, M Man, M Ramsjo, M Sanford, M Tseng, M Uhr, MA Kohli, MA Martin, MD Ritchie, ME van den Akker-van Marle, MH Tsai, Michael J McCarthy, MJ Arranz, MJ McCarthy, MJ Neville, ML Dahl, Naji C Salloum, OL de Klerk, OV Olesen, P Grof, P Huezo-Diaz, P Sklar, PS Klein, Psychiatric GWAS Consortium Bipolar Disorder Working Group, R Calati, R Hashimoto, RA Philibert, RC Kessler, RH Perlis, RH Perlis, RH Perlis, RH Perlis, RH Weisler, RJ Loos, RM Hirschfeld, RM Post, RS Seelan, S Horstmann, S Kapur, S Kapur, S Mallal, S Paddock, S Steinberg, S Ulrich, SC Sim, SG Leckband, SH Sindrup, SI Hung, SJ Gardiner, SL McElroy, Susan G Leckband, SV Ambudkar, T Bremer, T Masui, T Rau, T Ritchie, T Suppes, TD Gould, TE Klein, TL Horvath, V De Luca, VL Ellingrod, W Steimer, WB Denny, WH Chung, YF Lin, YF Zou, Z Wang, Z Wang   +172 more
core   +3 more sources

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source